An Open-Label, Phase I, Randomized Pharmacokinetic Study of Dietary Effects on Abiraterone Acetate Drug Levels in Patients With Metastatic Castration-Resistant Prostate Cancer (DEAL)

Trial Profile

An Open-Label, Phase I, Randomized Pharmacokinetic Study of Dietary Effects on Abiraterone Acetate Drug Levels in Patients With Metastatic Castration-Resistant Prostate Cancer (DEAL)

Discontinued
Phase of Trial: Phase I

Latest Information Update: 02 May 2017

At a glance

  • Drugs Abiraterone acetate (Primary)
  • Indications Adenocarcinoma; Prostate cancer
  • Focus Pharmacokinetics
  • Acronyms DEAL
  • Most Recent Events

    • 05 Jan 2015 Planned End Date changed from 1 Jan 2015 to 1 Jul 2015, as reported by ClinicalTrials.gov.
    • 05 Jan 2015 Status changed from recruiting to discontinued, as reported by ClinicalTrials.gov.
    • 07 Aug 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top